Skip to main content

Advertisement

Table 4 Multivariate analyses of factors associated with recurrence-free survival (RFS) in GIST patients with adjuvant imatinib therapy (*, P < 0.05)

From: Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome

Variable RFS hazard ratio (95% Cl) Pvalue
Tumor size (≤10, > 10 cm) 0.801 (0.222-2.889) 0.736
Mitosis count (≤10, > 10/50 HPF) 1.944 (0.546-6.913) 0.307
Serosal invasion (Yes, No) 3.549 (1.047-12.025) 0.043*